The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Predicting TMVR outcomes – the Tendyne experience

EuroIntervention 2019;15:e1033-e1034. DOI: 10.4244/EIJV15I12A193

1. Department of Interventional Cardiology, McGill University Health Centre, Montréal, Canada; 2. Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel


A decade after the first-in-human transcatheter mitral valve edge-to-edge repair, the first transcatheter mitral valve replacement (TMVR) was performed in 2012 by Lars Søndergaard (Copenhagen, Denmark) using the CardiAQ™ valve system (Edwards Lifesciences [previously CardiAQ Valve Technologies], Irvine, CA, USA) in patients with severe mitral regurgitation (MR)1. Seven years later, with fewer than 1,000 transcatheter mitral valve replacements (TMVR) performed worldwide, we are in the midst of performing randomised controlled trials comparing mitral valve surgery and TMVR in the USA, and potentially obtaining CE mark approval for TMVR systems in the near future. Prediction of procedural outcomes is ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
What constitutes sufficient clinical evidence for stents? SpotLITE on the evaluation of novel coronary devices